In Reply In our double-blind randomized noninferiority trial1 comparing placebo vs amoxicillin for nonsevere fast-breathing pneumonia in Malawian children aged 2 to 59 months, we were not able to show noninferiority of placebo but rather a slight yet statistically significant benefit from amoxicillin treatment.1 Our a priori trial hypothesis was consistent with the viewpoint of Woeltje et al; however, it was not supported by the data. While we agree most of these children do not require antibiotics to treat their fast-breathing pneumonia, a small number of children, even in this relatively low-risk population, appear to benefit from antibiotics based on our treatment failure criteria.
Ginsburg AS, McCollum ED, May SJ. World Health Organization Treatment Recommendations for Nonsevere Fast-Breathing Pneumonia Need to Be Updated—Reply. JAMA Pediatr. 2019;173(6):608–609. doi:10.1001/jamapediatrics.2019.0641
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: